Fortrea's revenue has stabilized, with year-over-year declines narrowing to -1.4% in 2026Q3 on $691.5M of revenue, and gross margin recovered to 20.2% from 16.3% in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.28+28.9% vs $0.22 | $692M+3.0% vs $672M |
Q3 2026 Jul 29, 2026 | $0.23+27.5% vs $0.18 | $678M+4.7% vs $648M |
Q2 2026 May 5, 2026 | $0.16+433.3% vs $0.03 | $637M+1.3% vs $629M |
Q1 2026 Feb 26, 2026 | $0.09-43.8% vs $0.16 | $661M-0.7% vs $665M |
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference:
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions Strengthens Fortrea's end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation Supports Fortrea's growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company's ability to create long-term value for shareholders Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials.
Benchmark FTRE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fortrea Holdings Inc. (FTRE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.96 | $2.09B | -32.35 | 1% | -2.58% | -12.81% | — | |
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — | |
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — | |
| $653.11 | $18.23B | 35.78 | 19.97% | 18.24% | 99.76% | — | |
| $204.74 | $15.68B | 35.32 | -0.37% | 5.45% | 4.85% | — | |
| $366.57 | $30.06B | 29.79 | 7.25% | 6.88% | 11.52% | 0.78% |
Fortrea Holdings Inc. (FTRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Fortrea Holdings Inc. (FTRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Sep 30, 2026·SEC
Jul 29, 2026·SEC
Get notified when FTRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fortrea Holdings Inc. (FTRE) stock FAQ — growth, dividends, profitability & financials explained
Fortrea Holdings Inc. (FTRE) reported $2.67B in revenue over the trailing twelve months. Revenue was $2.72B in fiscal year 2025. That is 11% less than the $3.06B of fiscal year 2021.
Fortrea Holdings Inc. (FTRE) revenue fell by 3.4% over the trailing twelve months, compared with the twelve months before.
No. Fortrea Holdings Inc. (FTRE) reported a net loss of $68.7M over the trailing twelve months.
Fortrea Holdings Inc. (FTRE) had a return on equity (ROE) of -12.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Fortrea Holdings Inc. (FTRE) generated $123.6M in free cash flow over the trailing twelve months.
